First Quarter Financial Report

15. May 2018 | 2 min read

Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include
  • Record level for total operating revenue of MNOK 11.2 for the quarter
  • 100 % growth in sales revenue compared to 1Q17
  • 24 % growth in sales revenue compared to 4Q17
  • Strong sales for both Cystatin C and fCal
  • New Proof-of-Concept announced post end of quarter

Please find the report enclosed. The report will also be made available on www.gentian.com.

 
For further information, please contact:
Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
 
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
 
 
MeldingsID:  451378
 
 

You may also read


May 06, 2026 - Ole Sørlie

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

Read more

May 06, 2026 - Ole Sørlie

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

Read more

May 06, 2026 - Ole Sørlie

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..

Read more